GeoffroyPineau-Valencienne

Partner

Paris + 33.1.56.59.39.39

Geoffroy Pineau-Valencienne has extensive experience in venture capital, private equity, M&A, and capital markets transactions. He represents a large number of private and public companies at every stage of development, from entrepreneurial start-ups to global corporations, particularly in the life sciences and technology fields, as well as financial and industrial investors.

He also represents, on a regular basis, tech and biopharmaceutical companies in transactional matters in relation to joint ventures and strategic partnerings, product development, distribution, and licensing agreements.

Geoffroy's recent experience includes representation of technology and life sciences companies such as Amoéba, Amolyt Pharma, Cellectis, Criteo, Enertime, Eurobio, Genticel, Inotrem, Mathym, Mauna Kea Technologies, Orega Biotech, Orphélia Pharma, Talend, Trace One, and Urban Canopée. His recent investor-side representations include: Alven, Andera, Balderton, BioMed, Bpifrance, CEA Investissement, CITA, Elaia, Fa-Dièse, Havenrock, HI Inov, Hil-Invest, Idinvest, Novo Holdings, Partech, Regenxbio, Riverside, Serena, Seventure, Supernova, Ventech, Wellington, and Western Digital.

Illustrative examples of the transactions in which Geoffroy acted as lead lawyer include IPOs and follow-on offerings (Amoéba, Genticel, and Enertime on the main or Growth market of Euronext Paris and Cellectis and Talend on Nasdaq), private and public M&A transactions (the acquisition of Pipplet by ETS Global; the sales of Alizé Pharma to Millendo, Mathym to Baikowski, Endocontrol to Canady Life Sciences, and SoCloz to Savoye; and the reverse merger of Genticel to Genkyotex), and venture capital financings, either on issuer- or investor-side (in connection with the financing rounds of Amolyt Pharma, Alédia, Inotrem, Mutabilis, Lendix, UpMem, Urban Canopée, UroMems, and TriCares).

Experience

  • Omnes Capital, IRDI Capital Investissement, Swen Capital Partners, and UL Holding S.A participate in €8.5 million investment in PeopleSpheresJones Day represented Omnes Capital, IRDI Capital Investissement, Swen Capital Partners, and UL Holding S.A. in connection with their participation in a €8.5 million investment in PeopleSpheres, a Paris, France-based developer of a SAAS solution for HR.
  • Bpifrance participates in $42 million Series B financing round of SightCallJones Day represented Bpifrance in the $42 million Series B round of financing of SightCall, Inc., the leading augmented reality (AR)-powered visual assistance platform, led by InfraVia Capital Partners.
  • Verizon Media forms partnership with BuzzFeed to acquire HuffPostJones Day advised Verizon Media in its sale of HuffPost to BuzzFeed.
  • Bpifrance participates in €80 million first tranche of €120 million Series D financing round of AlédiaJones Day represented Bpifrance in connection with the €80 million first tranche of a €120 million Series D financing of Alédia, a French company that develops and manufactures LED display technology based on a unique 3D architecture.
  • ETS Global acquires PippletJones Day represented ETS Global in connection with its acquisition of Pipplet, a start-up company specializing in language assessment for companies.
  • Wellington Partners, Bpifrance Investissement, CITA Investissement, Supernova Invest, b-to-v Partners, Hil-Invent, and Financière Arbevel participate in €16 million financing round of UroMemsJones Day represented Wellington Partners, Bpifrance Investissement, CITA Investissement, Supernova Invest, b-to-v Partners, Hil-Invent, and Financière Arbevel in connection with the €16 million new financing round of UroMems, a French medtech company focusing on designing, developing, and commercializing active implantable medical devices.
  • Alven, Fa Dièse and other main shareholders sell SoCloz to SavoyeJones Day advised Alven, Fa Dièse and other main shareholders in connection with the sale of SoCloz, a French company specialized in the development and marketing of SAAS software that allows retailers to digitize their points of sale and manage their omnicanality, to Savoye.
  • Inotrem raises €44 million in Series B roundJones Day advised Inotrem SA, a French biotech company specialized in immunotherapy for acute and chronic inflammatory syndromes, in connection with its €44 million Series B round of financing led by Morningside Ventures.
  • Novo Holdings REPAIR Impact Fund invests €7 million in MutabilisJones Day advised Novo Holdings REPAIR Impact Fund in connection with the €7 million convertible financing of Mutabilis, a French company engaged in the development of novel antibacterials against Gram-negative infections.
  • Mathym sold to BaikowskiJones Day advised the selling shareholders of Mathym, a French company operating in the area of nanomaterials and specializing in the development, manufacturing, and commercialization of nanodispersions, in its sale to Baikowski, a French manufacturer of specialist industrial minerals.
  • Setforge receives investment from BpifranceJones Day assisted Setforge, an affiliate of Farinia SA, in connection with the investment of Bpifrance via its Fonds Avenir Automobile (FAA) fund in Setforge.
  • Alizé Pharma 3 raises €67 million in financing roundJones Day represented Alizé Pharma 3 SAS, a French company engaged in the research and development of new therapeutic strategies for the treatment of rare endocrine and metabolic diseases, in connection with its €67 million (US$75 million) round of financing led by LSP, and included a syndicate of international investors.
  • Endocontrol sold to Canady Life Sciences, Inc.Jones Day advised Endocontrol, a French robotic company, and its main shareholders, Seventure Partners and ACG Management, in connection with its sale in a stock-for-stock transaction to Canady Life Sciences, Inc., a U.S. life sciences company.
  • Elaia Partners participates in €3.6 million Series A investment in PILIJones Day represented Elaia Partners in connection with its Series A investment in PILI, a French biotech company.
  • Havenrock participates in €4.4 million financing round of SESAMmJones Day assisted Havenrock SAS in connection with the €4.4 million (US$4.9 million) round of financing of a SESAMm, a French leader in Big Data and Artificial Intelligence solutions applied to asset management.
  • Athyrium Capital Management partially issues second tranche of bond issueJones Day advised Athyrium Capital Management, LP in connection with the partial issuance of the second tranche of its bond issue.
  • Fonds InnoBio acts as selling shareholder in reverse merger of Millendo Therapeutics with OvaScienceJones Day advised Fonds InnoBio, managed by Bpifrance, in connection with the reverse merger of Millendo Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, with OvaScience, Inc. in an all-stock transaction, and concurrent equity financing.
  • Creadev invests in InnovaFeedJones Day represented Creadev and Temasek in connection with their investment in InnovaFeed, a biotech company producing high quality insect meals for the feed industry.
  • Seventure and Entrepreneur Venture Gestion invest €6 million in IzicapJones Day advised Seventure Partners and Entrepreneur Venture Gestion in connection with the €6 million (US$6.9 million) Series A round of financing of Izicap, a provider of customer relationship marketing tools through consumers bank cards and existing payment terminals.
  • Wellington Partners, Andera Partners, and BioMed Partners invest €22 million in TRiCaresJones Day represented Wellington Partners, Andera Partners, and BioMed Partners in connection with the €22 million (US$25.4 million) Series B financing round of TRiCares SAS, a French medtech company pioneer in the field of minimally invasive treatment of tricuspid regurgitation.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.